On the 2nd, Dong-A Socio Holdings' subsidiary STgen Bio announced that it had signed a contract for contract manufacturing of biopharmaceuticals with a global pharmaceutical company. The total contract amount is 4.6 billion won, which corresponds to about 7.8% of the recent revenue of 58.8 billion won.
The contract period is from June of this year to November 2026. The advance payment is about 900 million won. The names of the client and the product remain confidential due to nondisclosure agreements. This contract is the second following a contract for manufacturing pharmaceuticals valued at 9.9 billion won that was awarded on the 13th of last month, with the recently awarded amount exceeding 14 billion won.
Focusing on the biopharmaceutical CMO business, STgen Bio proved its global quality competitiveness by passing inspections from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) last year.
It is a strength that, among domestic CMO companies, it is the only one that has a one-stop production system for raw materials (DS) to finished pharmaceuticals (DP) in a single location with cGMP-certified manufacturing facilities.
The company is focused on expanding collaboration with various partners in the global market. A spokesperson for STgen Bio noted, "STgen Bio provides production services covering the entire lifecycle from developmental samples to commercial products for DS and DP with high quality," emphasizing that it will strive to enhance its service platform across all areas of CMO to ensure that every client is satisfied.